MedTrace Logo

Rosuvastatin Evaluation as a Tuberculosis Treatment Adjunct

NCT04504851 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 154

Last updated 2020-08-07

No results posted yet for this study

Summary

This trial aims to determine whether the addition of rosuvastatin to standard TB therapy in pulmonary tuberculosis results in accelerated of sputum culture conversion. The trial will also investigate potential new biomarkers of sterilising activity and immune-modulatory activity.

Conditions

  • Pulmonary Tuberculosis

Interventions

DRUG

Rosuvastatin 10mg

10mg of Rosuvastatin in the Intensive Phase of Therapy (8 weeks)

DRUG

Rifampicin

Rifampicin 10mg/kg

DRUG

Isoniazid

Isoniazid 5mg/kg

DRUG

Pyrazinamide

Pyrazinamide 25mg/kg

DRUG

Ethambutol

Ethambutol 15mg/kg

Sponsors & Collaborators

  • National University Hospital, Singapore

    lead OTHER

Principal Investigators

  • Nicholas Paton · National University Hospital, Singapore

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-12
Primary Completion
2021-03-31
Completion
2021-03-31

Countries

  • Philippines
  • Singapore
  • Uganda
  • Vietnam

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04504851 on ClinicalTrials.gov